BMEA Stock Price, Chart, Stats & News
Biomea Fusion, Inc. (BMEA) does not currently pay a dividend.
BMEA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -105.51% |
ROE | -243.73% |
D/E | 0.05x |
Interest coverage ratio | – |
BMEA valuation
P/E | – |
P/S | – |
P/B | 3.23x |
P/CF | -1.36x |
P/FCF | -1.12x |
P/OCF | -1.36x |
PEG | -0.04x |
EV multiple | -1.72x |
About
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.
Similar securities
Based on sector and market capitalization
